OBSERVATION OF GRANISETRON AND DIFFERENT DOSES OF PALONOSETRON ON THE PREVENT10N 0F POSTOPERATIVE NAUSEA AND VOMITING (PONV)FOR EYE ENUCLEATION AND ORBITAL HYDROXYAPATITE IMPLANT SURGERY

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15005852

Enrollment

Unknown

Registered

2015-01-15

Start date

2015-01-20

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

POSTOPERATIVE NAUSEA AND VOMITING (PONV)FOR EYE ENUCLEATION AND ORBITAL HYDROXYAPATITE IMPLANT SURGERY

Interventions

granisetron:granisetron 40µg/kg

low dose palonosetron:palonosetron 2.5µg/kg

normal dose palonosetron:palonosetron 5µg/kg

large dose palonosetron:palonosetron 7.5µg/kg

palonosetron plus droperidol:palonosetron 2.5µg/kg plus droperidol15µg/kg

palonosetron plus dexamethasone:palonosetron 2.5µg/kg plus dexamethasone 0.1mg/kg

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: ASA I or II, age 18 to 70, BMI less than 30 kg/m2

Exclusion criteria

Exclusion criteria: Use antiemetic or steroid hormone drugs in 24 hours before surgen, BMI>30 kg/m2, with diseases of heart, brain, lung, liver and kidney

Design outcomes

Primary

Measure	Time frame
The severity of nausea and vomiting indifferent times;complete response;time to treatment failure;	—

Countries

China

Contacts

Public ContactTan Fang

tanfang1977@hotmail.com+86 13611716000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026